Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Multiprofen-CC is a multimodal topical cream formulated for the management of localized musculoskeletal pain, particularly in patients undergoing procedures such as total knee arthroplasty. It contains four active pharmaceutical ingredients: ketoprofen (10%), a non-steroidal anti-inflammatory drug (NSAID) that inhibits prostaglandin synthesis; baclofen (5%), a GABA-B receptor agonist and muscle relaxant; amitriptyline (2%), a tricyclic antidepressant with analgesic properties likely mediated by inhibition of norepinephrine and serotonin reuptake; and lidocaine (5%), a local anesthetic that blocks sodium channels to prevent nerve depolarization. The combination targets multiple pain pathways, aiming to provide enhanced analgesia while potentially reducing opioid requirements post-surgery. Multiprofen-CC is compounded for individual patients rather than mass-produced, with each ingredient approved by Health Canada[1][2][3][4][5].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on multiprofen-cc.